MSH|^~\&|LAB|RCH|||201911081446||ORU^R01|4103204|D|2.3|||AL|NE
PID|1||RC00007561|RC7336|LABTEST^ANA^||19700202|F||||||||||RC000202/19|9875287954
OBR|1|34522^LAB|00026530^2510:C00009R^LAB^251019:C9^34522|522.2490^BHCG^Beta-HCG^^^21198-7||201910250904|201910250700|||||||201910250904||||||||||LAB|F||||
NTE|1||Outside linearity low
OBX|1|ST|522.2510^BHCG R^Beta-HCG^^21198-7^21198-7|1|< 5^^Y|IU/L|<10|N||A^S|F|||201911081446
NTE|1||Reference Intervals, (guideline only) FOR B-HCG (U/L):
NTE|2||
NTE|3||Male or non-pregnant female            Less than 10
NTE|4||Pregnant female:
NTE|5||Time after LMP:        Expected beta-HCG range(WHO 3rd IRP):
NTE|6||4th  week                               25 - 426
NTE|7||5th  week                               25 - 7340
NTE|8||6th  week                             1080 - 56500
NTE|9||10th week                            54100 - 288000
NTE|10||18th week                             8910 - 66000
NTE|11||31st week                             5310 - 27400
NTE|12||*************************NOTE*******************************
NTE|13||Occasional patients with heterophile antibodies may have
NTE|14||erroneous BHCG results. Serum BHCG should not be used for
NTE|15||routine pregnancy tests. Urine does not contain heterophile
NTE|16||antibodies and may be used where apparent discrepant results
NTE|17||are experienced.
NTE|18||Method:Beckman Access/DxI